{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:32:37Z","timestamp":1794954757693,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) intensive chemotherapy combined with broad-spectrum antibiotics, leads to gut microbiota dysbiosis promoting pathological conditions and an increased incidence of complications. Here we report findings from a phase II single-arm, multicenter study evaluating autologous fecal microbiota transfer (AFMT) in 25 AML patients treated with intensive chemotherapy and antibiotics (ClinicalTrials.gov number: NCT02928523). The co-primary outcomes of the study are to evaluate the efficacy of AFMT in dysbiosis correction and multidrug-resistant bacteria eradication. The main secondary outcomes are to define a dysbiosis biosignature, to evaluate the effect of dysbiosis correction on patient clinical status, to assess the short and mid-term safety of AFMT in this immunocompromised population, and to evaluate the feasibility of the AFMT procedure and acceptability by the patient. Intensive induction chemotherapy induces a dramatic decrease of \u03b1-diversity indices, and a microbial dysbiosis with a significant shift of the microbial communities and domination of pro-inflammatory families. After AFMT treatment, \u03b1-diversity indices return to their initial mean levels and the similarity index shows the restoration of microbial communities. The trial meets pre-specified endpoints. AFMT appears to be safe and may be effective for gut microbiota restoration in AML patients receiving intensive chemotherapy and antibiotics, with an excellent gut microbiota reconstruction based on both richness and diversity indices at the species level.<\/jats:p>","DOI":"10.1038\/s41467-021-23376-6","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T06:02:59Z","timestamp":1621922579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lapusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Isnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"D\u2019incan-Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colombe","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ducastelle-Lepretre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Paubelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Virginie","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Gilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Plantamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Boucinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Gasc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricette","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"23376_CR1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"23376_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00520-015-2621-0","volume":"23","author":"K Mayer","year":"2015","unstructured":"Mayer, K. et al. Comparison of antibiotic prophylaxis with cotrimoxazole\/colistin (COT\/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia. Support Care Cancer 23, 1321\u20131329 (2015).","journal-title":"Support Care Cancer"},{"key":"23376_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.clml.2018.08.008","volume":"18","author":"W Owattanapanich","year":"2018","unstructured":"Owattanapanich, W., Owattanapanich, N., Kungwankiattichai, S., Ungprasert, P. & Ruchutrakool, T. Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin. Lymphoma Myeloma Leuk. 18, 814\u2013821.e813 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"23376_CR4","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/cncr.30039","volume":"122","author":"JR Galloway-Pena","year":"2016","unstructured":"Galloway-Pena, J. R. et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer 122, 2186\u20132196 (2016).","journal-title":"Cancer"},{"key":"23376_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-017-0409-1","volume":"9","author":"JR Galloway-Pe\u00f1a","year":"2017","unstructured":"Galloway-Pe\u00f1a, J. R. et al. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med. 9, 21\u201321 (2017).","journal-title":"Genome Med."},{"key":"23376_CR6","doi-asserted-by":"publisher","unstructured":"Galloway-Pe\u00f1a, J. R. et al. Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin. Infect. Dis. ciz777, https:\/\/doi.org\/10.1093\/cid\/ciz777 (2019).","DOI":"10.1093\/cid\/ciz777"},{"key":"23376_CR7","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","volume":"21","author":"SM Jandhyala","year":"2015","unstructured":"Jandhyala, S. M. et al. Role of the normal gut microbiota. World J. Gastroenterol. 21, 8787\u20138803 (2015).","journal-title":"World J. Gastroenterol."},{"key":"23376_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/apt.13302","volume":"42","author":"E Montassier","year":"2015","unstructured":"Montassier, E. et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Alimentary Pharmacol. Therapeutics 42, 515\u2013528 (2015).","journal-title":"Alimentary Pharmacol. Therapeutics"},{"key":"23376_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2015.05.014","volume":"159","author":"NW Palm","year":"2015","unstructured":"Palm, N. W., de Zoete, M. R. & Flavell, R. A. Immune-microbiota interactions in health and disease. Clin. Immunol. 159, 122\u2013127 (2015).","journal-title":"Clin. Immunol."},{"key":"23376_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/sj.thj.6200304","volume":"4","author":"A Camera","year":"2003","unstructured":"Camera, A. et al. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol. J. 4, 346\u2013350 (2003).","journal-title":"Hematol. J."},{"key":"23376_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.4065\/77.8.760","volume":"77","author":"WJ Hogan","year":"2002","unstructured":"Hogan, W. J. et al. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin. Proc. 77, 760\u2013762 (2002).","journal-title":"Mayo Clin. Proc."},{"key":"23376_CR12","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.11671","volume":"98","author":"LS Elting","year":"2003","unstructured":"Elting, L. S. et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98, 1531\u20131539 (2003).","journal-title":"Cancer"},{"key":"23376_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3109\/00365540903496569","volume":"42","author":"C Cattaneo","year":"2010","unstructured":"Cattaneo, C. et al. Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand. J. Infect. Dis. 42, 324\u2013332 (2010).","journal-title":"Scand. J. Infect. Dis."},{"key":"23376_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/cpt.923","volume":"103","author":"S Khanna","year":"2018","unstructured":"Khanna, S. Microbiota replacement therapies: innovation in gastrointestinal care. Clin. Pharm. Ther. 103, 102\u2013111 (2018).","journal-title":"Clin. Pharm. Ther."},{"key":"23376_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41409-018-0254-x","volume":"53","author":"F Malard","year":"2018","unstructured":"Malard, F., Gasc, C., Plantamura, E. & Dore, J. High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients. Bone Marrow Transplant. 53, 1493\u20131497 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"23376_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3109\/10428194.2011.636812","volume":"53","author":"G Cannas","year":"2012","unstructured":"Cannas, G. et al. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk. Lymphoma 53, 1068\u20131076 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"23376_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/MIB.0b013e3182807577","volume":"19","author":"S Nancey","year":"2013","unstructured":"Nancey, S. et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 19, 1043\u20131052 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"23376_CR18","doi-asserted-by":"publisher","first-page":"e0170003","DOI":"10.1371\/journal.pone.0170003","volume":"12","author":"R Wu","year":"2017","unstructured":"Wu, R. et al. Significance of serum total oxidant\/antioxidant status in patients with colorectal cancer. PLoS One 12, e0170003 (2017).","journal-title":"PLoS One"},{"key":"23376_CR19","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00018-017-2509-x","volume":"74","author":"GA Weiss","year":"2017","unstructured":"Weiss, G. A. & Hennet, T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol. Life Sci. 74, 2959\u20132977 (2017).","journal-title":"Cell Mol. Life Sci."},{"key":"23376_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-052918-122440","volume":"71","author":"ZI Schwabkey","year":"2020","unstructured":"Schwabkey, Z. I. & Jenq, R. R. Microbiome anomalies in allogeneic hematopoietic cell transplantation. Annu. Rev. Med 71, 137\u2013148 (2020).","journal-title":"Annu. Rev. Med"},{"key":"23376_CR21","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3389\/fmicb.2017.01765","volume":"8","author":"PD Cani","year":"2017","unstructured":"Cani, P. D. & de Vos, W. M. Next-generation beneficial microbes: the case of akkermansia muciniphila. Front. Microbiol. 8, 1765 (2017).","journal-title":"Front. Microbiol."},{"key":"23376_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"23376_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"23376_CR24","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3324\/haematol.2018.198549","volume":"104","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia, G. et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. Haematologica 104, 1682\u20131688 (2019).","journal-title":"Haematologica"},{"key":"23376_CR25","doi-asserted-by":"publisher","unstructured":"Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Translational Med. 10, https:\/\/doi.org\/10.1126\/scitranslmed.aap9489 (2018).","DOI":"10.1126\/scitranslmed.aap9489"},{"key":"23376_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/bloodadvances.2018017731","volume":"2","author":"Z DeFilipp","year":"2018","unstructured":"DeFilipp, Z. et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2, 745\u2013753 (2018).","journal-title":"Blood Adv."},{"key":"23376_CR27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2014-02-554725","volume":"124","author":"Y Taur","year":"2014","unstructured":"Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124, 1174\u20131182 (2014).","journal-title":"Blood"},{"key":"23376_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbmt.2014.01.030","volume":"20","author":"E Holler","year":"2014","unstructured":"Holler, E. et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol. Blood Marrow Transplant. 20, 640\u2013645 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"23376_CR29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1126\/science.aax3760","volume":"366","author":"CK Stein-Thoeringer","year":"2019","unstructured":"Stein-Thoeringer, C. K. et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 366, 1143\u20131149 (2019).","journal-title":"Science"},{"key":"23376_CR30","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbmt.2014.04.021","volume":"20","author":"F Malard","year":"2014","unstructured":"Malard, F. et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution\u2019s three decade experience. Biol. Blood Marrow Transplant. 20, 1217\u20131223 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"23376_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/cid\/cix252","volume":"65","author":"J Bilinski","year":"2017","unstructured":"Bilinski, J. et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin. Infect. Dis. 65, 364\u2013370 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"23376_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.bbmt.2016.02.009","volume":"22","author":"J Bilinski","year":"2016","unstructured":"Bilinski, J. et al. Impact of gut colonization by antibiotic-resistant bacteria on the outcomes of allogeneic hematopoietic stem cell transplantation: a retrospective, single-center study. Biol. Blood Marrow Transplant. 22, 1087\u20131093 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"23376_CR33","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508\u20131516 (2012).","journal-title":"Lancet"},{"key":"23376_CR34","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett, A. K. et al. A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125, 3878\u20133885 (2015).","journal-title":"Blood"},{"key":"23376_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-136604","volume":"136","author":"F Malard","year":"2020","unstructured":"Malard, F. et al. Successful and safe treatment of intestinal graft-versus-host disease (GvHD) with Pooled-Donor full ecosystem microbiota biotherapeutic: results from a 29 patient-cohort of a compassionate use\/expanded access treatment program. Blood 136, 15\u201315 (2020).","journal-title":"Blood"},{"key":"23376_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45173-4","volume":"9","author":"SD Burz","year":"2019","unstructured":"Burz, S. D. et al. A guide for ex vivo handling and storage of stool samples intended for fecal microbiota transplantation. Sci. Rep. 9, 8897 (2019).","journal-title":"Sci. Rep."},{"key":"23376_CR37","unstructured":"La transplantation de microbiote fe\u0301cal et son encadrement dans les essais cliniques. Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) (2016)."},{"key":"23376_CR38","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"23376_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"23376_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-3-r46","volume":"15","author":"DE Wood","year":"2014","unstructured":"Wood, D. E. & Salzberg, S. L. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 15, R46 (2014).","journal-title":"Genome Biol."},{"key":"23376_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nbt.2942","volume":"32","author":"J Li","year":"2014","unstructured":"Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834\u2013841 (2014).","journal-title":"Nat. Biotechnol."},{"key":"23376_CR42","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/blood.V130.Suppl_1.664.664","volume":"130","author":"M Mohty","year":"2017","unstructured":"Mohty, M. et al. Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in acute myeloid leukemia (AML) patients undergoing intensive treatment (ODYSSEE study): first results of a prospective multicenter trial. Blood 130, 2624\u20132624 (2017).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23376-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23376-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:22:19Z","timestamp":1669965739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23376-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23376"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23376-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M. reports lecture honoraria from Therakos\/Mallinckrodt, Biocodex, Janssen, Keocyt, Sanofi, JAZZ pharmaceuticals and Astellas, all outside the submitted work. J.D. received consultancy honoraria from MaaT Pharma and reports grants and\/or lecture honoraria from Janssen, Sanofi, MaaT Pharma, BMS, Nestle, Bridor and Danone. C.R.: Research grants (my institution: CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole): Abbvie, Amgen, Novartis, Celgene, JAZZ pharmaceuticals Agios, Daiichi-Sankyo, Astellas, Sunesis, Roche, MaaT Pharma. Advisory boards: Abbvie, Janssen, Jazz Pharma, Daiichi-Sankyo, Astellas, Novartis, Celgene, Otsuka, Sunesis, Roche, Otsuka, Macrogenics, Pfizer. S.B.: advisory board: Daiichi-Sankyo, Astellas, Jazz Pharma, Sanofi. Emilie Plantamura, Lilia Boucinha and Cyrielle Gasc are MaaT Pharma employees. Mohamad Mohty reports grants and\/or lecture honoraria from Janssen, Sanofi, MaaT Pharma, JAZZ pharmaceuticals, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche. The other authors did not disclose any relevant conflict of interest in relation to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3084"}}